<DOC>
	<DOCNO>NCT00751972</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness HeartWare® LVAD System patient list cardiac transplantation refractory , advanced heart failure risk death . The primary endpoint survival 180 day define alive originally implant HeartWare® LVAD transplant explanted recovery . Patient must survive 60 day post-explant recovery consider successful . Secondary endpoint include : - Overall survival - Incidence serious adverse event , neurocognitive status unanticipated adverse device effect . - Incidence device failure device malfunction - Quality Life improvement , measure Kansas City Cardiomyopathy Questionnaire ( KCCQ ) EuroQoL EQ-5D - Functional status improvement , measure New York Heart Association ( NYHA ) 6-minute walk The HeartWare® LVAD System approve US FDA November 20 , 2012 bridge cardiac transplantation ( reference PMA P100047 ) . Patients enrol study follow outcome six month , patient receive continue follow-up separate study .</brief_summary>
	<brief_title>Evaluation HeartWare Left Ventricular Assist Device Treatment Advanced Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Must least 18 year age enrollment . 2 . Body Surface Area ( BSA ) great equal 1.2 m2 . 3 . Patient NYHA Class IV 4 . Patient list cardiac transplantation 5 . Patient meet United Network Organ Sharing ( UNOS ) Status 1A 1B listing criterion . 6 . HeartWare® LVAD implant plan bridge transplant 7 . The patient legally authorize representative sign informed consent form 1 . Existence ongoing mechanical circulatory support ( MCS ) intraaortic balloon pump ( IABP ) 2 . Prior cardiac transplant . 3 . History confirm , untreated abdominal thoracic aortic aneurysm &gt; 5 cm . 4 . Cardiothoracic surgery within 30 day enrollment . 5 . Acute myocardial infarction within 14 day implant diagnosed ST T wave change ECG , diagnostic biomarkers , ongoing pain hemodynamic abnormality describe ( Figure 2 ) guideline publish ACC/AHA 2007 Guidelines Management Patients Unstable Angina/NonSTElevation Myocardial Infarction ; A Report American College Cardiology/American Heart Association Task Force Practice Guidelines . JACC Vol . 50 , No.7 , 2007 . 6 . On ventilator support &gt; 72 hour within four day immediately prior enrollment . 7 . Pulmonary embolus within three week enrollment document compute tomography ( CT ) scan nuclear scan . 8 . Symptomatic cerebrovascular disease &gt; 80 % carotid stenosis . 9 . Patients moderate severe aortic insufficiency without plan correction pump implantation surgery . 10 . Patients mechanical , animal human tissue heart valves exclude . 11 . Severe right ventricular failure define anticipate need right ventricular assist device ( RVAD ) support extracorporeal membrane oxygenation ( ECMO ) time HeartWare® LVAD screening/enrollment right atrial pressure &gt; 20 mmHg multiple inotropes , right ventricular ejection fraction ( RVEF ) &lt; 15 % clinical sign include low extremity edema , ascites pleural effusion refractory treatment diuretic two inotropic drug . 12 . Active , uncontrolled infection diagnose combination clinical symptom laboratory testing , include limited , continue positive culture , elevated temperature white blood cell ( WBC ) count , hypotension , tachycardia , generalize malaise despite appropriate antibiotic , antiviral antifungal treatment . 13 . Uncorrected thrombocytopenia generalize coagulopathy ( e.g. , platelet count &lt; 100,000 , INR &gt; 1.6 PTT &gt; 2.5 time control absence anticoagulation therapy ) . 14 . Intolerance anticoagulant antiplatelet therapy peri postoperative therapy investigator may administer base upon patient 's health status . 15 . Serum creatinine great 3.0 time upper limit normal within 48 hour study enrollment require dialysis ( include use ultrafiltration fluid removal ) . 16 . All three list liver enzymes [ AST ( SGOT ) , ALT ( SGPT ) , LDH ] &gt; 3 time upper limit normal total bilirubin &gt; 3 mg/dl within 24 hour study enrollment , biopsy proven liver cirrhosis portal hypertension . 17 . Pulmonary vascular resistance unresponsive ( fix ) pharmacologic manipulation demonstrate pulmonary artery systolic pressure exceed 60mmHg conjunction one three follow variable : Pulmonary vascular resistance great 5 Woods Units Pulmonary vascular resistance index great 6 Woods Units Transpulmonary gradient exceed 16 20 mmHg 18 . Patients require aortic , mitral , tricuspid pulmonary valve replacement ( include bioprosthetic valve ) leave ventricular ( LV ) aneurysm resection . 19 . Participation study involve investigational drug device . 20 . Severe illness , heart disease , would exclude cardiac transplantation . 21 . Pregnancy . 22 . Patient unwilling unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>